Trials / Terminated
TerminatedNCT02821819
Random-start Ovarian Stimulation in Egg-donors (ROSE)
Random-start Ovarian Stimulation in Egg-donors (ROSE) Trial: a Self-controlled Study
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Instituto Bernabeu · Academic / Other
- Sex
- Female
- Age
- 18 Years – 35 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this prospective single-center study is to evaluate the laboratory outcome after random start ovarian stimulation in oocyte donors. The study will be performed in egg-donors but this type of treatment has the potential to be implemented in general infertility population.
Detailed description
The study group will start ovarian stimulation randomly in different moments throughout the menstrual cycle. Randomization will take place on day 2-3 of the menstrual cycle, according to a list of random allocation of treatments and egg-donors will be assigned to random start ovarian stimulation: During follicular phase starting at day 5,7,9,11 or 13 of the menstrual cycle and during luteal phase starting at luteinizing hormone (LH) peak +3,+5,+7,+9 or +11. Egg-donors will receive urinary follicle stimulating hormone (FSH) 150-225 IU/d in gonadotropin-releasing hormone (GnRH) antagonist protocol with cetrorelix acetate 0,25 mg/d starting five days after ovarian stimulation and a GnRH agonist trigger with triptorelin 0,2 mg to induce the final follicular maturation. Transvaginal ultrasound and serum analysis (estradiol, progesterone, LH and FSH) will be included for cycle monitoring.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Random start ovarian stimulation | Egg-donors will start ovarian stimulation randomly at different moments throughout the menstrual cycle. |
| DRUG | Gonadotrophins | Urinary FSH 150-225 IU/d |
| DRUG | GnRH antagonist | Cetrorelix acetate 0,25 mg/d starting five days after ovarian stimulation |
| DRUG | GnRH agonist | GnRH agonist triggering with triptorelin 0,2 mg for final follicular maturation. |
Timeline
- Start date
- 2017-01-10
- Primary completion
- 2018-01-12
- Completion
- 2018-01-12
- First posted
- 2016-07-04
- Last updated
- 2019-08-19
- Results posted
- 2019-08-19
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT02821819. Inclusion in this directory is not an endorsement.